Blog
RSS FeedPosted by Michael Wonder on 01 Feb 2021
Determinants of managed entry agreements in the context of health technology assessment: a comparative analysis of oncology therapies in four countries
29 January 2021 - Managed entry agreements are increasingly used to address uncertainties arising in the health technology assessment process due ...
Posted by Michael Wonder on 31 Jan 2021
Evaluation of the impact of patient input in health technology assessments at NICE
29 January 2021 - Accounts of patient experiences are increasingly used in health technology assessment processes. However, we know little about ...
Posted by Michael Wonder on 27 Jan 2021
On the role of cost effectiveness thresholds in health care priority setting
25 January 2021 - In the past few years, empirical estimates of the marginal cost at which health care produces a ...
Posted by Michael Wonder on 24 Jan 2021
Creating a patient and community advisory committee at the Canadian Agency for Drugs and Technologies in Health
22 January 2021 - In recognition of patients’ roles using, and contributing to, a publicly funded health system, the Canadian Agency ...
Posted by Michael Wonder on 12 Jan 2021
STaRT-RWE: structured template for planning and reporting on the implementation of real world evidence studies
12 January 2021 - In alignment with the International Council of Harmonization’s strategic goals, a public private consortium has developed a ...
Posted by Michael Wonder on 11 Jan 2021
Evaluating New Zealanders’ values for drug coverage decision-making: trade-offs between treatments for rare and common conditions
8 January 2021 - The objectives of this study were to measure the relative societal importance of values of New Zealanders ...
Posted by Michael Wonder on 22 Dec 2020
Shared decision making is an integral part of healthcare, says NICE
22 December 2020 - Shared decision making between patients and clinicians should be embedded throughout healthcare services, says NICE, in draft ...
Posted by Michael Wonder on 07 Dec 2020
Update on funding decision for two new diabetes medicines
7 December 2020 - PHARMAC would like to thank everyone who has provided feedback to date on a proposal to ...
Posted by Michael Wonder on 06 Dec 2020
Government promises independent PHARMAC review after Labour MPs veto Health Select Committee inquiry
3 December 2020 - National MPs have lashed out at Labour for voting against a politician-led inquiry into PHARMAC but ...
Posted by Michael Wonder on 04 Dec 2020
ICER opens nominations for new members of its voting panels
2 December 2020 - Independent panel members debate the evidence on the effectiveness and value of new drugs and other ...
Posted by Michael Wonder on 04 Dec 2020
PHARMAC inquiry: “nothing should be off the table”
4 December 2020 - Medicines New Zealand, the industry association representing companies involved in the research, development and manufacture of ...
Posted by Michael Wonder on 03 Dec 2020
Fate of 250,000 diabetics in PHARMAC’s hands
3 December 2020 - This week, a small group of bureaucrats and health professionals will meet to agree on the ...
Posted by Michael Wonder on 12 Nov 2020
PHARMAC won’t release the data that changed its mind on diabetes
13 November 2020 - Diabetes Foundation Aotearoa will request the Ombudsman investigate the refusal by PHARMAC to release public submissions ...
Posted by Michael Wonder on 12 Nov 2020
Expertise, experience, and excellence. Twenty years of patient involvement in health technology assessment at NICE: an evolving story
10 November 2020 - From its inception in 1999, NICE committed to including the expertise, experiences, and perspectives of lay people, ...
Posted by Michael Wonder on 07 Nov 2020
A health opportunity cost threshold for cost effectiveness analysis in the United State
3 November 2020 - Cost effectiveness analysis is an important tool for informing treatment coverage and pricing decisions, yet no consensus ...